Vistin Pharma ASA (FRA:VP4)

Q1 2026 Vistin Pharma ASA Earnings Call Transcript

Apr 24, 2026 / 06:30AM GMT

Release Date Price: €2.03 (-1.93%)

Transcript

Key Points

Positve

Vistin Pharma ASA (STU:VP4) reported a strong sales volume of 1,520 metric tons in Q1 2026, marking a 9% increase compared to the same quarter last year.
The company maintained a gross margin of 63%, demonstrating good commercial execution despite currency effects.
Vistin Pharma ASA has built a significant safety stock of critical raw materials, mitigating potential supply chain interruptions due to geopolitical conflicts.
The company has a long-term renewable energy supply agreement ensuring predictable power prices and 100% green renewable hydropower until 2032.
Vistin Pharma ASA is strategically positioned to benefit from the growing global demand for metformin, with a market share of approximately 10%.

Negative

First quarter revenue decreased slightly to 112 million Norwegian kroner from 115 million in the same quarter last year.
EBITDA decreased to 27 million Norwegian kroner from 30 million in Q1 2025, affected by currency fluctuations.
The main distillation vessel has reached the end of its lifespan and will require replacement, leading to a planned four-week maintenance stop in Q4, impacting production and sales volume.
Increased freight and raw material prices are expected due to geopolitical tensions, potentially affecting future profitability.
The company faces challenges with volatile freight lead times and payment terms, particularly with Asian customers, impacting trade receivables.

Operator

Good day, and thank you for standing by. Welcome to the Vistin Pharma Quarterly Report Q1 2026 webcast and conference call. (Operator Instructions).

Alternatively, you may submit your questions via the webcast. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Maltro Stolesol, CEO. Please go ahead.

Magnus Tolleshaug

Vistin Pharma ASA - Chief Executive Officer

Thank you.

Good morning, everyone, and welcome to this first quarter 2026 presentation of Vistin Pharma ASA.

My name is Magnus Tolleshaug, CEO of the company.

And with me today, I have our CFO, Mr. Alexander Carson.

I will now go through the highlights.

The first quarter revenue ended at 112 million Norwegian kroner compared to 115 million in the first quarter last year.

We had a strong sales volume of 1,520 metric tons in the quarter, up 9%.

Compared to last year, offset by stronger Norwegian kroner versus euro and somewhat lower global metal mint

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.